CoNCERT

CTP-692 Phase 2 Topline Results

February 1, 2021



CTP-692: Phase 2 Trial Design

CoNCERT

A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of CTP-692 as an Adjunctive Treatment in Adults Patients with Schizophrenia



Most common background antipsychotic medications: Risperidone, Aripiprazole, Paliperidone, Olanzapine, Quetiapine

CTP-692 Phase 2: Patient Demographics

CoNCERT

	Placebo	CTP-692 1 gm	CTP-692 2 gm	CTP-692 4 gm
Safety Population, n	81	81	85	78
Efficacy Population, n	80	81	83	77
Age: Mean (SD)	42.1 (9.3%)	40.8 (9.0%)	42.7 (9.3%)	40.9 (9.7%)
Weight, kg (BMI)	88.9 (29.1)	95.6 (31.3)	89.5 (29.8)	90.5 (29.8)
Males, n (%)	60 (74.1%)	56 (69.1%)	60 (70.6%)	55 (70.5%)
Females, n (%)	21 (25.9%)	25 (30.9%)	25 (29.4%)	23 (29.5%)
White, n (%)	23 (28.4%)	18 (22.2%)	23 (27.1%)	26 (33.3%)
Black or African American, n (%)	49 (60.5%)	57 (70.4%)	57 (67.1%)	47 (60.3%)

CTP-692 Phase 2 Results: Primary Endpoint

CoNCERT



CTP-692 Phase 2 Results: Positive and Negative Subscales

CoNCERT





CTP-692 Phase 2: Treatment Emergent Adverse Events

CoNCERT

	Placebo (n = 81)	CTP-692 1 gm (n = 81)	CTP-692 2 gm (n = 85)	CTP-692 4 gm (n = 78)
Total # TEAEs	62	60	59	58
# Patients with TEAEs, n (%)	34 (42%)	37 (45.7%)	34 (40%)	34 (43.6%)
# Patients Moderate/Severe TEAEs, n (%)	14 (17.3%)	13 (16%)	14 (16.5%)	17 (21.8%)
Discontinuations due to TEAEs, n	3	2	2	4
Common (≥ 5%) Treatment Emergent Adverse Events (# Patients)				
Nausea	1 (1.2%)	1 (1.2%)	3 (3.5%)	4 (5.1%)
Headache	2 (2.5%)	4 (4.9%)	3 (3.5%)	4 (5.1%)

Two patients reported SAEs; both deemed unrelated to study drug.
Renal changes were observed across the cohorts, with a higher percentage in the placebo group.

CoNCERT

NASDAQ: CNCE
www.concertpharma.com
@ConcertPharma

For additional information contact:
Justine Koenigsberg
ir@concertpharma.com